2023 Q2 Form 10-Q Financial Statement
#000135657623000034 Filed on May 09, 2023
Income Statement
Concept | 2023 Q2 | 2023 Q1 |
---|---|---|
Revenue | $135.6M | $153.8M |
YoY Change | -20.28% | 0.82% |
Cost Of Revenue | $21.09M | $23.46M |
YoY Change | 3.1% | 30.83% |
Gross Profit | $114.5M | $130.3M |
YoY Change | -23.48% | -3.17% |
Gross Profit Margin | 84.44% | 84.74% |
Selling, General & Admin | $86.78M | $85.60M |
YoY Change | -13.63% | -5.37% |
% of Gross Profit | 75.81% | 65.69% |
Research & Development | $24.38M | $21.21M |
YoY Change | 48.79% | 1.79% |
% of Gross Profit | 21.3% | 16.28% |
Depreciation & Amortization | $20.73M | $20.60M |
YoY Change | -3.86% | -3.56% |
% of Gross Profit | 18.1% | 15.81% |
Operating Expenses | $111.2M | $106.8M |
YoY Change | -4.88% | -4.03% |
Operating Profit | -$17.59M | $5.176M |
YoY Change | -255.01% | 163.14% |
Interest Expense | $910.0K | $1.505M |
YoY Change | -49.72% | -22.5% |
% of Operating Profit | 29.08% | |
Other Income/Expense, Net | $460.0K | $3.841M |
YoY Change | -2190.91% | -69.89% |
Pretax Income | -$17.13M | $9.017M |
YoY Change | -251.25% | -38.76% |
Income Tax | -$16.30M | -$7.900M |
% Of Pretax Income | -87.61% | |
Net Earnings | -$831.0K | $16.95M |
YoY Change | -110.57% | -33.84% |
Net Earnings / Revenue | -0.61% | 11.02% |
Basic Earnings Per Share | -$0.02 | $0.31 |
Diluted Earnings Per Share | -$0.02 | $0.29 |
COMMON SHARES | ||
Basic Shares Outstanding | 54.48M shares | 54.38M shares |
Diluted Shares Outstanding | 54.50M shares | 62.45M shares |
Balance Sheet
Concept | 2023 Q2 | 2023 Q1 |
---|---|---|
SHORT-TERM ASSETS | ||
Cash & Short-Term Investments | $151.7M | $228.6M |
YoY Change | -57.97% | -26.79% |
Cash & Equivalents | $24.71M | $58.44M |
Short-Term Investments | $127.0M | $170.1M |
Other Short-Term Assets | $44.77M | $420.1M |
YoY Change | 109.09% | 1777.6% |
Inventory | $90.56M | $91.15M |
Prepaid Expenses | ||
Receivables | $136.6M | $143.6M |
Other Receivables | $0.00 | $0.00 |
Total Short-Term Assets | $423.5M | $883.3M |
YoY Change | -32.25% | 55.38% |
LONG-TERM ASSETS | ||
Property, Plant & Equipment | $14.19M | $14.61M |
YoY Change | -13.06% | -15.13% |
Goodwill | $117.0M | $117.0M |
YoY Change | 1.39% | 1.39% |
Intangibles | $662.4M | $682.5M |
YoY Change | -10.9% | -10.67% |
Long-Term Investments | $37.48M | $54.16M |
YoY Change | -74.57% | -56.79% |
Other Assets | $38.49M | $40.18M |
YoY Change | -18.7% | -17.97% |
Total Long-Term Assets | $869.6M | $908.5M |
YoY Change | -18.72% | -15.18% |
TOTAL ASSETS | ||
Total Short-Term Assets | $423.5M | $883.3M |
Total Long-Term Assets | $869.6M | $908.5M |
Total Assets | $1.293B | $1.792B |
YoY Change | -23.71% | 9.29% |
SHORT-TERM LIABILITIES | ||
YoY Change | ||
Accounts Payable | $4.400M | $11.54M |
YoY Change | -87.61% | -6.32% |
Accrued Expenses | $83.04M | $95.35M |
YoY Change | -37.56% | 6.61% |
Deferred Revenue | ||
YoY Change | ||
Short-Term Debt | $0.00 | $480.9M |
YoY Change | -100.0% | |
Long-Term Debt Due | ||
YoY Change | ||
Total Short-Term Liabilities | $252.6M | $731.5M |
YoY Change | -65.66% | 157.08% |
LONG-TERM LIABILITIES | ||
Long-Term Debt | $0.00 | $0.00 |
YoY Change | -100.0% | |
Other Long-Term Liabilities | $8.734M | $8.614M |
YoY Change | -27.0% | -39.1% |
Total Long-Term Liabilities | $8.734M | $8.614M |
YoY Change | -27.0% | -39.1% |
TOTAL LIABILITIES | ||
Total Short-Term Liabilities | $252.6M | $731.5M |
Total Long-Term Liabilities | $8.734M | $8.614M |
Total Liabilities | $373.2M | $879.7M |
YoY Change | -56.28% | 8.46% |
SHAREHOLDERS EQUITY | ||
Retained Earnings | $497.4M | $498.2M |
YoY Change | 9.55% | 11.66% |
Common Stock | $55.00K | $54.00K |
YoY Change | 3.77% | 1.89% |
Preferred Stock | ||
YoY Change | ||
Treasury Stock (at cost) | ||
YoY Change | ||
Treasury Stock Shares | ||
Shareholders Equity | $919.9M | $912.2M |
YoY Change | ||
Total Liabilities & Shareholders Equity | $1.293B | $1.792B |
YoY Change | -23.71% | 9.29% |
Cashflow Statement
Concept | 2023 Q2 | 2023 Q1 |
---|---|---|
OPERATING ACTIVITIES | ||
Net Income | -$831.0K | $16.95M |
YoY Change | -110.57% | -33.84% |
Depreciation, Depletion And Amortization | $20.73M | $20.60M |
YoY Change | -3.86% | -3.56% |
Cash From Operating Activities | -$18.87M | $49.13M |
YoY Change | -126.54% | 1041.93% |
INVESTING ACTIVITIES | ||
Capital Expenditures | $159.0K | $278.0K |
YoY Change | -72.4% | -132.67% |
Acquisitions | ||
YoY Change | ||
Other Investing Activities | $60.45M | $240.1M |
YoY Change | -471.92% | -447.23% |
Cash From Investing Activities | $60.30M | $239.8M |
YoY Change | -484.57% | -442.61% |
FINANCING ACTIVITIES | ||
Cash Dividend Paid | ||
YoY Change | ||
Common Stock Issuance & Retirement, Net | ||
YoY Change | ||
Debt Paid & Issued, Net | ||
YoY Change | ||
Cash From Financing Activities | -478.9M | $80.17M |
YoY Change | -21169.78% | -463.86% |
NET CHANGE | ||
Cash From Operating Activities | -18.87M | $49.13M |
Cash From Investing Activities | 60.30M | $239.8M |
Cash From Financing Activities | -478.9M | $80.17M |
Net Change In Cash | -437.5M | $369.1M |
YoY Change | -858.05% | -520.75% |
FREE CASH FLOW | ||
Cash From Operating Activities | -$18.87M | $49.13M |
Capital Expenditures | $159.0K | $278.0K |
Free Cash Flow | -$19.03M | $48.85M |
YoY Change | -126.98% | 847.95% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2023Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001356576 | |
CY2023Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2023Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2023Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2023 | |
CY2023Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
CY2021 | us-gaap |
Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
|
http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member | |
CY2023Q1 | us-gaap |
Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent | |
CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent | |
CY2022Q4 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent | |
CY2023Q1 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent | |
CY2023Q1 | us-gaap |
Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent | |
CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent | |
CY2023Q1 | dei |
Document Type
DocumentType
|
10-Q | |
CY2023Q1 | dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | |
CY2023Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2023-03-31 | |
CY2023Q1 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2023Q1 | dei |
Entity File Number
EntityFileNumber
|
001-35518 | |
CY2023Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
SUPERNUS PHARMACEUTICALS, INC. | |
CY2023Q1 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
CY2023Q1 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
20-2590184 | |
CY2023Q1 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
9715 Key West Avenue | |
CY2023Q1 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Rockville | |
CY2023Q1 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
MD | |
CY2023Q1 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
20850 | |
CY2023Q1 | dei |
City Area Code
CityAreaCode
|
301 | |
CY2023Q1 | dei |
Local Phone Number
LocalPhoneNumber
|
838-2500 | |
CY2023Q1 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2023Q1 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2023Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Large Accelerated Filer | |
CY2023Q1 | dei |
Entity Small Business
EntitySmallBusiness
|
false | |
CY2023Q1 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
CY2023Q1 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2023Q1 | dei |
Security12b Title
Security12bTitle
|
Common Stock, $0.001 par value per share | |
CY2023Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
54476409 | shares |
CY2023Q1 | dei |
Trading Symbol
TradingSymbol
|
SUPN | |
CY2023Q1 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
CY2023Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
58442000 | usd |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
93120000 | usd |
CY2023Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
403758000 | usd |
CY2022Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
0 | usd |
CY2023Q1 | us-gaap |
Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
|
170126000 | usd |
CY2022Q4 | us-gaap |
Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
|
368214000 | usd |
CY2023Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
143568000 | usd |
CY2022Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
165497000 | usd |
CY2023Q1 | us-gaap |
Inventory Net
InventoryNet
|
91147000 | usd |
CY2022Q4 | us-gaap |
Inventory Net
InventoryNet
|
91541000 | usd |
CY2023Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
16299000 | usd |
CY2022Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
15779000 | usd |
CY2023Q1 | us-gaap |
Assets Current
AssetsCurrent
|
883340000 | usd |
CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
734151000 | usd |
CY2023Q1 | us-gaap |
Debt Securities Available For Sale Excluding Accrued Interest Noncurrent
DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
|
54157000 | usd |
CY2022Q4 | us-gaap |
Debt Securities Available For Sale Excluding Accrued Interest Noncurrent
DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
|
93896000 | usd |
CY2023Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
14611000 | usd |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
15173000 | usd |
CY2023Q1 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
682497000 | usd |
CY2022Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
702463000 | usd |
CY2023Q1 | us-gaap |
Goodwill
Goodwill
|
117019000 | usd |
CY2022Q4 | us-gaap |
Goodwill
Goodwill
|
117019000 | usd |
CY2023Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
40184000 | usd |
CY2022Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
39806000 | usd |
CY2023Q1 | us-gaap |
Assets
Assets
|
1791808000 | usd |
CY2022Q4 | us-gaap |
Assets
Assets
|
1702508000 | usd |
CY2023Q1 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
95345000 | usd |
CY2022Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
96342000 | usd |
CY2023Q1 | supn |
Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
|
147852000 | usd |
CY2022Q4 | supn |
Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
|
151665000 | usd |
CY2023Q1 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
402500000 | usd |
CY2022Q4 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
401968000 | usd |
CY2023Q1 | us-gaap |
Lines Of Credit Current
LinesOfCreditCurrent
|
78363000 | usd |
CY2022Q4 | us-gaap |
Lines Of Credit Current
LinesOfCreditCurrent
|
0 | usd |
CY2023Q1 | us-gaap |
Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
|
0 | usd |
CY2022Q4 | us-gaap |
Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
|
21120000 | usd |
CY2023Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
7485000 | usd |
CY2022Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
16863000 | usd |
CY2023Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
731545000 | usd |
CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
687958000 | usd |
CY2023Q1 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
53320000 | usd |
CY2022Q4 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
33847000 | usd |
CY2023Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
36511000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
35998000 | usd |
CY2023Q1 | us-gaap |
Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
|
49668000 | usd |
CY2022Q4 | us-gaap |
Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
|
49809000 | usd |
CY2023Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
8614000 | usd |
CY2022Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
8692000 | usd |
CY2023Q1 | us-gaap |
Liabilities
Liabilities
|
879658000 | usd |
CY2022Q4 | us-gaap |
Liabilities
Liabilities
|
816304000 | usd |
CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2023Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2023Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
130000000 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
130000000 | shares |
CY2023Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
54470622 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
54470622 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
54253796 | shares |
CY2023Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
54253796 | shares |
CY2023Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
54000 | usd |
CY2022Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
54000 | usd |
CY2023Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
416232000 | usd |
CY2022Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
408115000 | usd |
CY2023Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-2329000 | usd |
CY2022Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-3210000 | usd |
CY2023Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
498193000 | usd |
CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
481245000 | usd |
CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
912150000 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
886204000 | usd |
CY2023Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1791808000 | usd |
CY2022Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1702508000 | usd |
CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
153764000 | usd |
CY2022Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
152506000 | usd |
CY2023Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
23460000 | usd |
CY2022Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
17932000 | usd |
CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
21212000 | usd |
CY2022Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
20839000 | usd |
CY2023Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
85597000 | usd |
CY2022Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
90459000 | usd |
CY2023Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
19966000 | usd |
CY2022Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
20644000 | usd |
CY2023Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
-1647000 | usd |
CY2022Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
665000 | usd |
CY2023Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
148588000 | usd |
CY2022Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
150539000 | usd |
CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
5176000 | usd |
CY2022Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
1967000 | usd |
CY2023Q1 | us-gaap |
Interest Expense
InterestExpense
|
1505000 | usd |
CY2022Q1 | us-gaap |
Interest Expense
InterestExpense
|
1942000 | usd |
CY2023Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
5346000 | usd |
CY2022Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
14698000 | usd |
CY2023Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
3841000 | usd |
CY2022Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
12756000 | usd |
CY2023Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
9017000 | usd |
CY2022Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
14723000 | usd |
CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-7931000 | usd |
CY2022Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-10893000 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
16948000 | usd |
CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
25616000 | usd |
CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.31 | |
CY2022Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.48 | |
CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.29 | |
CY2022Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.43 | |
CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
54380947 | shares |
CY2022Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
53330837 | shares |
CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
62454204 | shares |
CY2022Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
61406555 | shares |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
16948000 | usd |
CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
25616000 | usd |
CY2023Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
881000 | usd |
CY2022Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-2312000 | usd |
CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
881000 | usd |
CY2022Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-2312000 | usd |
CY2023Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
17829000 | usd |
CY2022Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
23304000 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
886204000 | usd |
CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
6306000 | usd |
CY2023Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
1811000 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
16948000 | usd |
CY2023Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
881000 | usd |
CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
912150000 | usd |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
815851000 | usd |
CY2022Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
4025000 | usd |
CY2022Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
866000 | usd |
CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
25616000 | usd |
CY2022Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-2312000 | usd |
CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
828446000 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
16948000 | usd |
CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
25616000 | usd |
CY2023Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
20601000 | usd |
CY2022Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
21362000 | usd |
CY2023Q1 | us-gaap |
Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
|
0 | usd |
CY2022Q1 | us-gaap |
Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
|
12888000 | usd |
CY2023Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
532000 | usd |
CY2022Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
526000 | usd |
CY2023Q1 | us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
1056000 | usd |
CY2022Q1 | us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
360000 | usd |
CY2023Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
-1647000 | usd |
CY2022Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
665000 | usd |
CY2023Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-2459000 | usd |
CY2022Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-84000 | usd |
CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
6306000 | usd |
CY2022Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
4025000 | usd |
CY2023Q1 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-435000 | usd |
CY2022Q1 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-13011000 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-21971000 | usd |
CY2022Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-3812000 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1851000 | usd |
CY2022Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
2468000 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
341000 | usd |
CY2022Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1061000 | usd |
CY2023Q1 | supn |
Increase Decrease In Accrued Product Returns And Rebates
IncreaseDecreaseInAccruedProductReturnsAndRebates
|
-3813000 | usd |
CY2022Q1 | supn |
Increase Decrease In Accrued Product Returns And Rebates
IncreaseDecreaseInAccruedProductReturnsAndRebates
|
7457000 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-10548000 | usd |
CY2022Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-29479000 | usd |
CY2023Q1 | supn |
Increase Decrease In Contingent Consideration
IncreaseDecreaseInContingentConsideration
|
0 | usd |
CY2022Q1 | supn |
Increase Decrease In Contingent Consideration
IncreaseDecreaseInContingentConsideration
|
-2100000 | usd |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
49126000 | usd |
CY2022Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
4302000 | usd |
CY2023Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
0 | usd |
CY2022Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
98063000 | usd |
CY2023Q1 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
240058000 | usd |
CY2022Q1 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
28927000 | usd |
CY2023Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
278000 | usd |
CY2022Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
851000 | usd |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
239780000 | usd |
CY2022Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-69987000 | usd |
CY2023Q1 | us-gaap |
Proceeds From Short Term Debt
ProceedsFromShortTermDebt
|
93000000 | usd |
CY2022Q1 | us-gaap |
Proceeds From Short Term Debt
ProceedsFromShortTermDebt
|
0 | usd |
CY2023Q1 | us-gaap |
Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
|
14637000 | usd |
CY2022Q1 | us-gaap |
Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
|
0 | usd |
CY2023Q1 | us-gaap |
Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
|
0 | usd |
CY2022Q1 | us-gaap |
Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
|
22900000 | usd |
CY2023Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
1811000 | usd |
CY2022Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
866000 | usd |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
80174000 | usd |
CY2022Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-22034000 | usd |
CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
369080000 | usd |
CY2022Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-87719000 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
93120000 | usd |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
203434000 | usd |
CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
462200000 | usd |
CY2022Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
115715000 | usd |
CY2023Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
0 | usd |
CY2022Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
1258000 | usd |
CY2023Q1 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
203000 | usd |
CY2022Q1 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
478000 | usd |
CY2023Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
3457000 | usd |
CY2022Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
2949000 | usd |
CY2023Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
2601000 | usd |
CY2022Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
27000 | usd |
CY2023Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
0 | usd |
CY2022Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
549000 | usd |
CY2023Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
Business Organization<div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supernus Pharmaceuticals, Inc. (the "Company", see Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has eight commercial products that it markets: Qelbree</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trokendi XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Oxtellar XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, GOCOVRI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, APOKYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, XADAGO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Osmolex ER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and MYOBLOC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, SPN-830 (apomorphine infusion device) is a late-stage drug/device combination product candidate for the continuous treatment of motor fluctuations ("off" episodes) in PD patients that are not adequately controlled with oral levodopa and one or more adjunct PD medications.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adamas Reorganization</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022, the Company completed a reorganization of the Adamas Pharmaceuticals, Inc. (Adamas) legal entities in an effort to obtain operational, legal and other benefits that also resulted in certain state tax efficiencies. The reorganization had no effect on the condensed consolidated financial statements other than certain state tax efficiencies. (See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Benefit</span>. | |
CY2023Q1 | supn |
Number Of Commercial Products
NumberOfCommercialProducts
|
8 | product |
CY2023Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | segment |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
93120000 | usd |
CY2023Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
403758000 | usd |
CY2023Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition and results of operations is highly uncertain and subject to change. As a result, certain of our estimates and assumptions, including the provision for sales deductions and the fair values of our financial instruments, and the recoverability of intangible assets require increased judgment and carry a higher degree of variability and volatility that could result in material changes to our estimates in future periods.</span></div> | |
CY2023Q1 | us-gaap |
Advertising Expense
AdvertisingExpense
|
25900000 | usd |
CY2022Q1 | us-gaap |
Advertising Expense
AdvertisingExpense
|
23900000 | usd |
CY2023Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
403800000 | usd |
CY2023Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
58442000 | usd |
CY2022Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
0 | usd |
CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
462200000 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
93120000 | usd |
CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
153764000 | usd |
CY2022Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
152506000 | usd |
CY2023Q1 | supn |
Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
|
2300000 | usd |
CY2022Q1 | supn |
Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
|
2200000 | usd |
CY2023Q1 | us-gaap |
Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss Current
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent
|
227331000 | usd |
CY2022Q4 | us-gaap |
Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss Current
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent
|
466333000 | usd |
CY2023Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
0 | usd |
CY2022Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
14000 | usd |
CY2023Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
3048000 | usd |
CY2022Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
4237000 | usd |
CY2023Q1 | us-gaap |
Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
|
224283000 | usd |
CY2022Q4 | us-gaap |
Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
|
462110000 | usd |
CY2023Q1 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
170126000 | usd |
CY2023Q1 | supn |
Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year Two
DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo
|
42713000 | usd |
CY2023Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
80.91 | |
CY2023Q1 | supn |
Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year Three
DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree
|
11444000 | usd |
CY2023Q1 | supn |
Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year Four
DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour
|
0 | usd |
CY2023Q1 | supn |
Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Thereafter
DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateThereafter
|
0 | usd |
CY2023Q1 | us-gaap |
Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
|
224283000 | usd |
CY2023Q1 | us-gaap |
Debt Securities Available For Sale Excluding Accrued Interest Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded
|
0 | usd |
CY2021Q4 | us-gaap |
Proceeds From Divestiture Of Businesses And Interests In Affiliates
ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates
|
12900000 | usd |
CY2021Q4 | us-gaap |
Proceeds From Divestiture Of Businesses And Interests In Affiliates
ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates
|
12900000 | usd |
CY2022Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
54967000 | usd |
CY2023Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
|
1647000 | usd |
CY2023Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
53320000 | usd |
CY2021Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
80477000 | usd |
CY2022Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
|
25000000 | usd |
CY2022Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
|
-665000 | usd |
CY2022Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
56142000 | usd |
CY2022Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
|
25000000 | usd |
CY2022Q1 | us-gaap |
Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
|
22900000 | usd |
CY2022Q1 | us-gaap |
Payment For Contingent Consideration Liability Operating Activities
PaymentForContingentConsiderationLiabilityOperatingActivities
|
2100000 | usd |
CY2023Q1 | us-gaap |
Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
|
0 | usd |
CY2022Q4 | us-gaap |
Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
|
21120000 | usd |
CY2023Q1 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
53320000 | usd |
CY2022Q4 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
33847000 | usd |
CY2023Q1 | us-gaap |
Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
|
53320000 | usd |
CY2022Q4 | us-gaap |
Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
|
54967000 | usd |
CY2023Q1 | us-gaap |
Finite Lived Intangible Assets Remaining Amortization Period1
FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
|
P7Y5M26D | |
CY2023Q1 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
849320000 | usd |
CY2023Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
166823000 | usd |
CY2023Q1 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
682497000 | usd |
CY2022Q4 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
849320000 | usd |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
146857000 | usd |
CY2022Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
702463000 | usd |
CY2023Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
20000000 | usd |
CY2022Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
20600000 | usd |
CY2023Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
80.91 | |
CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
6306000 | usd |
CY2022Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4025000 | usd |
CY2023Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
80.91 | |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
16948000 | usd |
CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
25616000 | usd |
CY2023Q1 | us-gaap |
Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
|
892000 | usd |
CY2022Q1 | us-gaap |
Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
|
887000 | usd |
CY2023Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
17840000 | usd |
CY2022Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
26503000 | usd |
CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
54380947 | shares |
CY2022Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
53330837 | shares |
CY2023Q1 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
1289321 | shares |
CY2022Q1 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
1291782 | shares |
CY2023Q1 | us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
6783936 | shares |
CY2022Q1 | us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
6783936 | shares |
CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
62454204 | shares |
CY2022Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
61406555 | shares |
CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.31 | |
CY2022Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.48 | |
CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.29 | |
CY2022Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.43 | |
CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-7931000 | usd |
CY2022Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-10893000 | usd |
CY2023Q1 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
-0.880 | |
CY2022Q1 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
-0.740 | |
CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-7900000 | usd |
CY2022Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-10900000 | usd |
CY2023Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
30022000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
28904000 | usd |
CY2023Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
30022000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
28904000 | usd |
CY2023Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
7576000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
6791000 | usd |
CY2023Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
36511000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
35998000 | usd |
CY2023Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
44087000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
42789000 | usd |
CY2023Q1 | supn |
Allowance For Expected Sales Deductions
AllowanceForExpectedSalesDeductions
|
12200000 | usd |
CY2022Q4 | supn |
Allowance For Expected Sales Deductions
AllowanceForExpectedSalesDeductions
|
13000000 | usd |
CY2023Q1 | us-gaap |
Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
|
22917000 | usd |
CY2022Q4 | us-gaap |
Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
|
24820000 | usd |
CY2023Q1 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
33975000 | usd |
CY2022Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
31710000 | usd |
CY2023Q1 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
34255000 | usd |
CY2022Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
35011000 | usd |
CY2023Q1 | us-gaap |
Inventory Net
InventoryNet
|
91147000 | usd |
CY2022Q4 | us-gaap |
Inventory Net
InventoryNet
|
91541000 | usd |
CY2022Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
10543000 | usd |
CY2023Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
15978000 | usd |
CY2023Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
28295000 | usd |
CY2022Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
28222000 | usd |
CY2023Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
13684000 | usd |
CY2022Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
13049000 | usd |
CY2023Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
14611000 | usd |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
15173000 | usd |
CY2023Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
600000 | usd |
CY2022Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
700000 | usd |
CY2023Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
11544000 | usd |
CY2022Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
16783000 | usd |
CY2023Q1 | supn |
Accrued Manufacturing Expenses
AccruedManufacturingExpenses
|
14943000 | usd |
CY2022Q4 | supn |
Accrued Manufacturing Expenses
AccruedManufacturingExpenses
|
15216000 | usd |
CY2023Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
14433000 | usd |
CY2022Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
16963000 | usd |
CY2023Q1 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
11892000 | usd |
CY2022Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
12022000 | usd |
CY2023Q1 | supn |
Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
|
8158000 | usd |
CY2022Q4 | supn |
Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
|
7490000 | usd |
CY2023Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
7576000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
6791000 | usd |
CY2023Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
10821000 | usd |
CY2022Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
10534000 | usd |
CY2023Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
95345000 | usd |
CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
96342000 | usd |
CY2023Q1 | supn |
Accrued Rebates
AccruedRebates
|
98812000 | usd |
CY2022Q4 | supn |
Accrued Rebates
AccruedRebates
|
106657000 | usd |
CY2023Q1 | supn |
Accrued Product Returns
AccruedProductReturns
|
49040000 | usd |
CY2022Q4 | supn |
Accrued Product Returns
AccruedProductReturns
|
45008000 | usd |
CY2023Q1 | supn |
Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
|
147852000 | usd |
CY2022Q4 | supn |
Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
|
151665000 | usd |
CY2023Q1 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
1188000 | usd |
CY2022Q1 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
1155000 | usd |
CY2023Q1 | us-gaap |
Interest Expense Other
InterestExpenseOther
|
317000 | usd |
CY2022Q1 | us-gaap |
Interest Expense Other
InterestExpenseOther
|
787000 | usd |
CY2023Q1 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
1505000 | usd |
CY2022Q1 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
1942000 | usd |
CY2023Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
500000 | usd |
CY2022Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
500000 | usd |
CY2014Q3 | supn |
Non Recourse Debt Sale Of Future Royalties Noncurrent
NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent
|
30000000 | usd |